{"id":"https://openalex.org/W2124357503","doi":"https://doi.org/10.1002/wsbm.1210","title":"Developing melanoma therapeutics: overview and update","display_name":"Developing melanoma therapeutics: overview and update","publication_year":2013,"publication_date":"2013-02-13","ids":{"openalex":"https://openalex.org/W2124357503","doi":"https://doi.org/10.1002/wsbm.1210","mag":"2124357503","pmid":"https://pubmed.ncbi.nlm.nih.gov/23408545"},"language":"en","primary_location":{"id":"doi:10.1002/wsbm.1210","doi":"https://doi.org/10.1002/wsbm.1210","is_oa":false,"landing_page_url":"https://doi.org/10.1002/wsbm.1210","pdf_url":null,"source":{"id":"https://openalex.org/S113440077","display_name":"WIREs Systems Biology and Medicine","issn_l":"1939-005X","issn":["1939-005X","1939-5094"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","norway-1","poland-100"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"WIREs Systems Biology and Medicine","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088733311","display_name":"John B. Korman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John B. Korman","raw_affiliation_strings":["Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210087915"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078874539","display_name":"David E. Fisher","orcid":"https://orcid.org/0000-0002-5506-0575","observed_orcids":["https://orcid.org/0000-0002-5506-0575"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"David E. Fisher","raw_affiliation_strings":["Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210087915"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5078874539"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210087915"],"apc_list":{"value":4000,"currency":"USD","value_usd":4000},"apc_paid":null,"fwci":0.3376,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":{"value":0.2887404,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"5","issue":"3","first_page":"257","last_page":"271"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9470000267028809},{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":0.906000018119812},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.8970000147819519},{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.9070000052452087},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.9279999732971191},{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.8289999961853027},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.765999972820282},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.593999981880188},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.7829999923706055},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.9679999947547913},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.5720000267028809},{"id":"https://openalex.org/keywords/melanoma-subtypes","display_name":"melanoma subtypes","score":0.5809999704360962}],"concepts":[{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.8853964805603027},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7989283800125122},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6695171594619751},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.666110634803772},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.5435258746147156},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.5139031410217285},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.5015511512756348},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.44812482595443726},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.428437739610672},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.41854211688041687},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.3931957185268402},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.38371503353118896},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37905579805374146},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.31992781162261963},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.31885188817977905},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.145625501871109},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077484","descriptor_name":"Vemurafenib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D013602","descriptor_name":"T-Lymphocytes, Cytotoxic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013602","descriptor_name":"T-Lymphocytes, Cytotoxic","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D013602","descriptor_name":"T-Lymphocytes, Cytotoxic","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D020928","descriptor_name":"Mitogen-Activated Protein Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D020929","descriptor_name":"Mitogen-Activated Protein Kinase Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D020929","descriptor_name":"Mitogen-Activated Protein Kinase Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/wsbm.1210","doi":"https://doi.org/10.1002/wsbm.1210","is_oa":false,"landing_page_url":"https://doi.org/10.1002/wsbm.1210","pdf_url":null,"source":{"id":"https://openalex.org/S113440077","display_name":"WIREs Systems Biology and Medicine","issn_l":"1939-005X","issn":["1939-005X","1939-5094"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","norway-1","poland-100"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"WIREs Systems Biology and Medicine","raw_type":"journal-article"},{"id":"pmid:23408545","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23408545","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Wiley interdisciplinary reviews. Systems biology and medicine","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":83,"referenced_works":["https://openalex.org/W1270711560","https://openalex.org/W1487731794","https://openalex.org/W1950572133","https://openalex.org/W1967902354","https://openalex.org/W1978195308","https://openalex.org/W1982972087","https://openalex.org/W1989121777","https://openalex.org/W1990011632","https://openalex.org/W1990376228","https://openalex.org/W1999025555","https://openalex.org/W2004295816","https://openalex.org/W2009228205","https://openalex.org/W2009642188","https://openalex.org/W2010121426","https://openalex.org/W2017187984","https://openalex.org/W2020543365","https://openalex.org/W2020727013","https://openalex.org/W2020855013","https://openalex.org/W2024085992","https://openalex.org/W2032211985","https://openalex.org/W2035000040","https://openalex.org/W2040851929","https://openalex.org/W2040910597","https://openalex.org/W2043058822","https://openalex.org/W2043724107","https://openalex.org/W2046585589","https://openalex.org/W2050206485","https://openalex.org/W2051165598","https://openalex.org/W2053520756","https://openalex.org/W2055624262","https://openalex.org/W2057243929","https://openalex.org/W2063264144","https://openalex.org/W2065786604","https://openalex.org/W2066671159","https://openalex.org/W2069032357","https://openalex.org/W2071483270","https://openalex.org/W2073620629","https://openalex.org/W2073924618","https://openalex.org/W2094366129","https://openalex.org/W2095826876","https://openalex.org/W2096575630","https://openalex.org/W2097995306","https://openalex.org/W2100158834","https://openalex.org/W2100614336","https://openalex.org/W2101653483","https://openalex.org/W2106494998","https://openalex.org/W2106543129","https://openalex.org/W2108789863","https://openalex.org/W2109511835","https://openalex.org/W2109653150","https://openalex.org/W2115328641","https://openalex.org/W2118471749","https://openalex.org/W2118863192","https://openalex.org/W2122639773","https://openalex.org/W2123363005","https://openalex.org/W2128542677","https://openalex.org/W2129400742","https://openalex.org/W2129623370","https://openalex.org/W2134471382","https://openalex.org/W2136474966","https://openalex.org/W2137723371","https://openalex.org/W2141674733","https://openalex.org/W2141830999","https://openalex.org/W2142859055","https://openalex.org/W2143467222","https://openalex.org/W2145138996","https://openalex.org/W2147474070","https://openalex.org/W2154196978","https://openalex.org/W2155104279","https://openalex.org/W2155461614","https://openalex.org/W2156078931","https://openalex.org/W2157016650","https://openalex.org/W2159697541","https://openalex.org/W2160834915","https://openalex.org/W2161550811","https://openalex.org/W2163188200","https://openalex.org/W2165948908","https://openalex.org/W2166262263","https://openalex.org/W2168143310","https://openalex.org/W2169332496","https://openalex.org/W2172131454","https://openalex.org/W2203317209","https://openalex.org/W2602152747"],"related_works":["https://openalex.org/W2124912877","https://openalex.org/W1803616539","https://openalex.org/W1967000639","https://openalex.org/W2061339803","https://openalex.org/W2537774629","https://openalex.org/W2025130458","https://openalex.org/W2571001524","https://openalex.org/W2753512521","https://openalex.org/W1986494983","https://openalex.org/W42439289"],"abstract_inverted_index":{"Melanoma":[0],"is":[1],"a":[2,59],"common,":[3],"often":[4],"deadly":[5],"malignancy,":[6],"historically":[7],"associated":[8],"with":[9],"limited":[10],"treatment":[11],"options":[12],"for":[13,95],"advanced":[14],"disease.":[15],"In":[16],"recent":[17],"years,":[18],"systems-based":[19],"research":[20],"has":[21],"resulted":[22],"in":[23,53,64,107],"significant":[24],"clinical":[25,163],"advancements.":[26],"Strategic":[27],"inhibition":[28],"of":[29,34,129,139,152,173,192],"mutated":[30],"oncoproteins":[31],"and":[32,48,98,118,137,149,162,184,190],"targeting":[33],"immune":[35],"checkpoints":[36],"have":[37],"emerged":[38],"as":[39,132,134],"very":[40],"promising":[41],"approaches.":[42],"Vemurafenib,":[43],"which":[44],"received":[45],"US":[46],"Food":[47],"Drug":[49],"Administration":[50],"(FDA)":[51],"approval":[52],"2011,":[54],"selectively":[55],"inhibits":[56],"BRAF(V600E)":[57],",":[58],"hyperactivated":[60],"mutant":[61],"signaling":[62],"kinase":[63,68],"the":[65,77,127,135,170],"mitogen-activated":[66],"protein":[67],"(MAPK)":[69],"pathway.":[70],"Another":[71],"recently":[72],"FDA-approved":[73],"drug,":[74],"ipilimumab,":[75],"blocks":[76],"cytotoxic":[78],"T-lymphocyte":[79],"antigen-4":[80],"(CTLA-4)":[81],"pathway":[82],"from":[83],"inhibiting":[84],"T":[85],"cell":[86],"activation.":[87],"Despite":[88],"this":[89],"apparent":[90],"progress,":[91],"compelling":[92],"challenges":[93],"remain":[94,103],"both":[96],"researchers":[97],"clinicians.":[99],"Responses":[100],"to":[101,116,167,175,185],"therapy":[102],"unacceptably":[104],"incomplete":[105],"and,":[106],"most":[108,182],"cases,":[109],"resistance":[110,156],"mechanisms":[111],"quickly":[112],"develop":[113],"that":[114,179],"lead":[115],"relapse":[117],"subsequent":[119],"patient":[120],"mortality.":[121],"Combining":[122],"therapeutic":[123],"modalities":[124],"may":[125],"increase":[126],"percentage":[128],"responding":[130],"patients":[131],"well":[133],"magnitude":[136],"durability":[138],"response.":[140],"Notably,":[141],"combined":[142],"therapies":[143],"involving":[144],"selective":[145],"BRAF":[146],"inhibitors":[147,151],"(SBIs)":[148],"other":[150],"MAPK-dependent":[153],"or":[154],"MAPK-independent":[155],"pathways":[157],"appear":[158],"particularly":[159],"promising.":[160],"Preclinical":[161],"studies":[164],"are":[165],"needed":[166],"comprehensively":[168],"evaluate":[169],"optimal":[171,187],"combinations":[172],"therapies,":[174],"identify":[176],"melanoma":[177],"subtypes":[178],"will":[180],"be":[181],"responsive,":[183],"determine":[186],"dosing,":[188],"timing,":[189],"route":[191],"delivery.":[193]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}